|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAP3K6 |
Gene summary for MAP3K6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAP3K6 | Gene ID | 9064 |
| Gene name | mitogen-activated protein kinase kinase kinase 6 | |
| Gene Alias | ASK2 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O95382 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9064 | MAP3K6 | P4_S8_cSCC | Human | Skin | cSCC | 1.31e-05 | 1.29e-01 | -0.3095 |
| 9064 | MAP3K6 | P5_S10_cSCC | Human | Skin | cSCC | 1.47e-02 | 1.11e-01 | -0.299 |
| 9064 | MAP3K6 | P1_cSCC | Human | Skin | cSCC | 4.67e-19 | 5.81e-01 | 0.0292 |
| 9064 | MAP3K6 | P2_cSCC | Human | Skin | cSCC | 2.02e-10 | 2.88e-01 | -0.024 |
| 9064 | MAP3K6 | P4_cSCC | Human | Skin | cSCC | 2.73e-04 | 2.18e-01 | -0.00290000000000005 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAP3K6 | SNV | Missense_Mutation | novel | c.1007N>G | p.Ser336Cys | p.S336C | O95382 | protein_coding | deleterious(0.02) | benign(0.432) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MAP3K6 | SNV | Missense_Mutation | rs778880492 | c.3532G>A | p.Glu1178Lys | p.E1178K | O95382 | protein_coding | tolerated(0.13) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MAP3K6 | SNV | Missense_Mutation | c.2077N>C | p.Glu693Gln | p.E693Q | O95382 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| MAP3K6 | SNV | Missense_Mutation | novel | c.2635G>T | p.Ala879Ser | p.A879S | O95382 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAP3K6 | SNV | Missense_Mutation | novel | c.980G>T | p.Arg327Met | p.R327M | O95382 | protein_coding | tolerated(0.12) | possibly_damaging(0.478) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAP3K6 | SNV | Missense_Mutation | c.3051N>C | p.Glu1017Asp | p.E1017D | O95382 | protein_coding | tolerated(0.11) | benign(0) | TCGA-C5-A0TN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| MAP3K6 | SNV | Missense_Mutation | novel | c.3766G>A | p.Asp1256Asn | p.D1256N | O95382 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| MAP3K6 | SNV | Missense_Mutation | rs199627707 | c.3478G>A | p.Ala1160Thr | p.A1160T | O95382 | protein_coding | tolerated(0.62) | benign(0.012) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MAP3K6 | SNV | Missense_Mutation | rs760353235 | c.826A>T | p.Ile276Phe | p.I276F | O95382 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MAP3K6 | SNV | Missense_Mutation | novel | c.692C>G | p.Ser231Cys | p.S231C | O95382 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FU-A40J-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9064 | MAP3K6 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565813 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |